Crucell Terug naar discussie overzicht

Crucell Announces STAR® Research License Agr

1. [verwijderd] 29 april 2008 07:50

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Published: 07:45 29.04.2008 GMT+2 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562
   
   Crucell Announces STAR® Research License Agreement with Toyobo Gene Analysis Co. LTD.
   
   Leiden, The Netherlands, 29 April 2008 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR® research license agreement with Toyobo Gene Analysis Co. LTD. Under the agreement, Toyobo Gene Analysis will evaluate Crucell's STAR® technology for generating cell lines for the production of recombinant proteins for third-party customers. Financial details of the agreement were not disclosed.
   
   About STAR® Technology
   STAR® technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6® human cell technology and the widely used Chinese hamster ovary (CHO) cell line. STAR® technology contains genetic elements, called STAR® elements that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology has the potential to increase production yields, thereby reducing production costs.
   
   About Crucell
   Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biotechnology company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Portugal, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.
   
   About Toyobo Gene Analysis
   TGAC (Osaka, Japan) established as a wholly-owned subsidiary of TOYOBO Co., Ltd., (Toyobo) in 1992 and since then it has contributed to "Toyobo's Biotech" in its role as one of domestic gene analyze company that can handle the human samples. In April of 2004, the biochemical research and contract manufacturing section was separated from Toyobo and joined TGAC. TGAC got possible to provide service to gene analysis, genetic recombination, cell culture and protein production for pre-clinical and clinical use. For more information see: www.toyobo.co.jp/e/index.htm Contact: info_tgac@toyobo.jp
   
   
   Forward-looking statements
   This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in Europe (IFRS).
2. bv.tanden 29 april 2008 08:02

   auteur info

   • bv.tanden

     Lid sinds: 28 aug 2003

     Laatste bezoek: 04 okt 2023

   • Aanbevelingen

     Ontvangen: 59

     Gegeven: 594

   •    Aantal posts: 327

   Mooi mooi, dit wordt de DMS voor Azie zo aan de naam te zien
3. wilb52 29 april 2008 08:11

   auteur info

   • wilb52

     Lid sinds: 01 jan 2000

     Laatste bezoek: 08 jul 2022

   • Aanbevelingen

     Ontvangen: 1701

     Gegeven: 224

   •    Aantal posts: 5.104

   DSM denk ik
4. bv.tanden 29 april 2008 08:16

   auteur info

   • bv.tanden

     Lid sinds: 28 aug 2003

     Laatste bezoek: 04 okt 2023

   • Aanbevelingen

     Ontvangen: 59

     Gegeven: 594

   •    Aantal posts: 327

   Ja, idd, DSM natuurlijk
5. Huppeldepepup 29 april 2008 10:52

   auteur info

   • Huppeldepepup

     Lid sinds: 19 feb 2004

     Laatste bezoek: 13 mei 2024

   • Aanbevelingen

     Ontvangen: 1433

     Gegeven: 577

   •    Aantal posts: 4.902

   Het lijkt niemand iets te doen, op de beurs.
6. SJC 29 april 2008 11:01

   auteur info

   • SJC

     Lid sinds: 29 sep 2004

     Laatste bezoek: 13 mei 2024

   • Aanbevelingen

     Ontvangen: 28

     Gegeven: 308

   •    Aantal posts: 197

   Het zijn inhoudelijk ook nietszeggende persberichten. Dus hoe moet je er op reageren?
7. gogogoo 29 april 2008 11:05

   auteur info

   • gogogoo

     Lid sinds: 28 feb 2006

     Laatste bezoek: 10 aug 2023

   • Aanbevelingen

     Ontvangen: 1600

     Gegeven: 808

   •    Aantal posts: 6.042

   quote:

   Huppeldepepup schreef:

   Het lijkt niemand iets te doen, op de beurs.
   

   De koers gaat pas als die mag gaan. Als er uit de laat iets gekocht is volgt er meteen weer een dumpje op de bied naar de 12,30 a 12,29. Het mag gewoon even niet.
   
   Het PB leidde er alleen even toe dat er met iets meer stukjes de koers teruggezet moest worden naar de slotkoers van gisteren.
8. gogogoo 29 april 2008 11:28

   auteur info

   • gogogoo

     Lid sinds: 28 feb 2006

     Laatste bezoek: 10 aug 2023

   • Aanbevelingen

     Ontvangen: 1600

     Gegeven: 808

   •    Aantal posts: 6.042

   Via crucell.yourbb.nl
   
   "DSM verwacht recordjaar na zeer sterk eerste kwartaal
   
   Heerlen,NL,29-apr-2008 08:15 CET
   
   ..... en de omvangrijke investeringsplannen voor DSM Dyneema. Wij zijn ervan overtuigd dat DSM een goede uitgangspositie heeft om de kansen te benutten die de markten ons bieden .’ "
   
   Nippon Dyneema Co., Ltd. Manufacture of high-performance fiber "DYNEEMA"
   www.toyobo.co.jp/e/annai/groupcompany...
   
   DYNEEMA® is manufactured in Nippon Dyneema Co., Ltd (Osaka,Japan),
   a joint venture established by DSM Dyneema (Urmond, Holland) and Toyobo,
   www.toyobo.co.jp/e/seihin/dn/dyneema/
9. Huppeldepepup 29 april 2008 11:33

   auteur info

   • Huppeldepepup

     Lid sinds: 19 feb 2004

     Laatste bezoek: 13 mei 2024

   • Aanbevelingen

     Ontvangen: 1433

     Gegeven: 577

   •    Aantal posts: 4.902

   Toch valt me op, dat we de laatste tijd weer meer horen over STAR. STAR was drie jaar geleden dé grote belofte van Crucell (althans, volgens sommigen). Nadat het twee jaar doodstil was, komen nu weer af en toe wat berichten. Is het vertrouwen toegenomen? Is, ondanks dat nog nooit echt evaluatieresultaten bekend zijn gemaakt, in de biowereld toch de overtuiging ontstaan dat het werkt? Volgens mij zijn dit belangrijker berichten, dan uit de reactie blijkt. Blijkbaar moeten we nog steeds rustig afwachten.
10. [verwijderd] 29 april 2008 12:16

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Precies.
    De spijker op z'n kop. Niet vernoemd op de laatste CC, maar STAR begint langszaam aan een factor in de markt te worden.
    Genzyme heeft meegewerkt hoor aan het publiceren van de eerste resultaten. Bij SCRIPPS is e.e.a. al eens uit de doeken gedaan.
    
    Als ik plaatjes uit een pdf-presentatie hier kon plaatsen, dan zou ik dat zeker doen.
    
    Het gaat alleeeeen nog wel erg lang duren voordat STAR in een productie-omgeving wordt ingezet. Je moet een PERC.6-achtig geduld kunnen opbrengen voordat dit (aanzienlijk harder dan PERC.6) aantikt.
11. flosz 29 april 2008 12:53

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 22 jun 2023

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    quote:

    Huppeldepepup schreef:

    Nadat het twee jaar doodstil was, komen nu weer af en toe wat berichten.
    

    Vandaag in ieder geval nr. 4....en dat in de vierde mnd.
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    
    Maar doodstil was het zeer zeker niet....
    
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    investors.crucell.com/C/132631/PR/200...
    
    Trends Biotechnol. 2006 Feb 3; [Epub ahead of print] Related Articles, Links
    Employing epigenetics to augment the expression of therapeutic proteins in mammalian cells.
    
    Kwaks TH, Otte AP.
    ChromaGenics, Kruislaan 406, 1098 SM, Amsterdam, The Netherlands.
    
    Recombinant proteins form an increasingly large part of the portfolio of biopharmaceutical companies. Production of these often complex transgenic proteins is achieved predominantly in mammalian cell lines but the process is hampered by low yields and unstable expression. Some of these problems are caused by gene silencing at the level of chromatin - so-called epigenetic gene silencing. Here, we describe approaches, which have emerged during the past few years, designed to interfere with epigenetic gene silencing with the aim of enhancing and stabilizing transgene expression. These include targeting histones, the inclusion of specific DNA elements and targeting sites of high gene-expression. We conclude that employing epigenetic gene regulation tools, in combination with further process optimization, might represent the next step forward in the production of therapeutic proteins.
    www.aseanbiotechnology.info/Abstract/...
    J Biotechnol. 2006 Oct 10;
    
    A novel, high stringency selection system allows screening of few clones for high protein expression.
    van Blokland HJ, Kwaks TH, Sewalt RG, Verhees JA, Klaren VN, Siersma TK, Korse JW, Teunissen NC, Botschuijver S, van Mer C, Man SY, Otte AP.
    
    ChromaGenics, Kruislaan 406, 1098 SM Amsterdam, The Netherlands.
    To obtain highly productive mammalian cell lines, often large numbers of clones need to be screened. This is largely due to low selection stringencies, creating many, but low protein producing clones. To remedy this problem, a novel, very stringent selection system was designed, to create few, but high protein producing clones. In essence, a selection marker with a startcodon that confers attenuated translation initiation frequency was placed upstream of the gene of interest with a startcodon that confers optimal translation initiation. From the transcribed bicistronic mRNA, the selection marker is translated at a low frequency, and the protein of interest at a high frequency. This selection system is so stringent that clones form only rarely. However, application of anti-repressor elements, which increase promoter activity, did induce the formation of clones that expressed proteins at high levels. When combined with anti-repressor elements, this novel selection system can be a valuable tool to rapidly create few, but highly productive mammalian cell lines.
    PMID: 17092592
    www.ncbi.nlm.nih.gov/pubmed/17092592?...
    
12. flosz 29 april 2008 12:54

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 22 jun 2023

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    ....en meer uit Crucell's biotechnological box of tricks
    
    Biotechnol Prog. 2007 Jun 22;
    Various Expression-Augmenting DNA Elements Benefit from STAR-Select, a Novel High Stringency Selection System for Protein Expression.
    
    Otte AP, Kwaks TH, Blokland RJ, Sewalt RG, Verhees J, Klaren VN, Siersma TK, Korse HW, Teunissen NC, Botschuijver S, Mer CV, Man SY.
    ChromaGenics, Kruislaan 406, 1098 SM, Amsterdam, The Netherlands, and Swammerdam Institute for Life Sciences, University of Amsterdam, Kruislaan 406, 1098 SM, Amsterdam, The Netherlands.
    
    The creation of highly productive mammalian cell lines often requires the screening of large numbers of clones, and even then expression levels are often low. Previously, we identified DNA elements, anti-repressor or STAR elements, that increase protein expression levels. These positive effects of STAR elements are most apparent when stable clones are established under high selection stringency. We therefore developed a very high selection system, STAR-Select, that allows the formation of few but highly productive clones. Here we compare the influence of STAR and other expression-augmenting DNA elements on protein expression levels in CHO-K1 cells. The comparison is done in the context of the often-used cotransfection selection procedure and in the context of the STAR-Select system. We show that STAR elements, as well as MAR elements induce the highest protein expression levels with both selection systems. Furthermore, in trans cotransfection of multiple copies of STAR and MAR elements also results in higher protein expression levels. However, highest expression levels are achieved with the STAR-Select selection system, when STAR elements or MARs are incorporated in a single construct. Our results also show that the novel STAR-Select selection system, which was developed in the context of STAR elements, is also very beneficial for the use of MAR elements.
    PMID: 17585780
    
    Beyond its development of various vaccines and proteins, the company (Crucell) was also positive about developments with its STAR technology, which Crucell said enabled biotechnology firm Genzyme to develop protein-producing cells more rapidly than using existing systems.
    Crucell's CEO said the tests were done using a protein that is difficult to
    reproduce and the company called the results "positive".
    Genzyme was able to significantly increase protein production per
    production cell up to 70 pg/cell/day using STAR® Technology
    hugin.info/132631/R/1156099/223030.pdf
    hugin.info/132631/R/1146394/218126.pdf
    
    Recently, a novel selection system has been developed called STAR™-Select. The combination of STAR™-Select and STAR™-elements allows selection at such high stringencies that only a few very high producing clones – containing STAR™-elements - survive, resulting in significant reductions in both timelines and resources in cell clone generation programs.
    STAR® technology supports high yield antibody & protein production. Using Crucell’s STAR® technology, high levels of protein can be generated. This has been demonstrated in several CHO derivatives for several proteins and different antibodies. Under standard non-optimized cell culture conditions using commercially available medium, specific productivity levels ranging between 25 and 70 pg /cell/day are easily achieved with screening of only up to 50 clones.
    
13. flosz 29 april 2008 13:10

    auteur info

    • flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 22 jun 2023

    • Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    We are market forerunners in Japan, having the largest contract manufacturing business for antibody drugs. This business complies with the world standard, the Current Good Manufacturing Practice (cGMP) by the Food and Drug Administration (FDA) in the U.S., and it is attracting much attention of the pharmaceutical industry both in Japan and overseas.
    
    crucell.yourbb.nl/viewtopic.php?f=20&...